Literature DB >> 30816132

Ex Vivo 1H NMR study of pituitary adenomas to differentiate various immunohistochemical subtypes.

Omkar B Ijare1, David S Baskin2,3, Kumar Pichumani4,5.   

Abstract

Pituitary adenomas (PAs) are benign growths arising from epithelial cells in the adenohypophysis of the pituitary gland. To date, there has been no detailed metabolic characterization of PAs of various subtypes. In this study, we report nuclear magnetic resonance (NMR) based metabolomic analysis of surgically resected tumors from forty five pituitary tumor patients [gonadotropic (LH/FSH-secreting) = 17; prolactinomas (PRL-secreting) = 11, Cushing's disease (ACTH-secreting) = 4, non-functional = 5, and mixed = 8] who underwent transsphenoidal selective adenomectomy. Compared to LH/FSH-secreting tumors, PRL-secreting tumors showed statistically significant decrease in the levels of N-acetylaspartate (NAA), myo-inositol (mI), scyllo-inositol (sI), glycine, taurine, phosphoethanolamine (PE) and increase in the levels of glutamine. When compared with LH/FSH-secreting tumors, ACTH-secreting tumors showed statistically significant decrease in the levels of sI, glycine, PE and increase in the levels of aspartate. Although lipid extracts of PAs showed the presence of many common lipid molecules, only glycerophosphoethanolamine (GPE) showed statistically significant decrease in PRL, ACTH and non-functional subtypes when compared to LH/FSH-secreting tumors. Changes observed in these metabolite concentrations among various subtypes of PAs reflect metabolic heterogeneity in these tumors and may pave the way towards the development of metabolic markers to distinguish various immunohistochemical subtypes of PAs.

Entities:  

Year:  2019        PMID: 30816132      PMCID: PMC6395808          DOI: 10.1038/s41598-019-38542-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  6 in total

1.  Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.

Authors:  Omkar B Ijare; Shashank Hambarde; Fabio Henrique Brasil da Costa; Sophie Lopez; Martyn A Sharpe; Santosh A Helekar; Gilbert Hangel; Wolfgang Bogner; Georg Widhalm; Robert M Bachoo; David S Baskin; Kumar Pichumani
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

Review 2.  Machine learning applications in imaging analysis for patients with pituitary tumors: a review of the current literature and future directions.

Authors:  Ashirbani Saha; Samantha Tso; Jessica Rabski; Alireza Sadeghian; Michael D Cusimano
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 3.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

4.  In situ solid-state NMR study of antimicrobial peptide interactions with erythrocyte membranes.

Authors:  Kiran Kumar; Mathew Sebastiao; Alexandre A Arnold; Steve Bourgault; Dror E Warschawski; Isabelle Marcotte
Journal:  Biophys J       Date:  2022-03-09       Impact factor: 3.699

5.  Proton Magnetic Resonance Spectroscopy Characterization of Rathke's Cleft Cysts (RCCs): Relevance to the Differential Diagnosis of Pituitary Adenomas and RCCs.

Authors:  Omkar B Ijare; Martyn A Sharpe; David S Baskin; Kumar Pichumani
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

6.  Elevated levels of circulating betahydroxybutyrate in pituitary tumor patients may differentiate prolactinomas from other immunohistochemical subtypes.

Authors:  Omkar B Ijare; Cole Holan; Jonathan Hebert; Martyn A Sharpe; David S Baskin; Kumar Pichumani
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.